Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

PHASE4UnknownINTERVENTIONAL

Enrollment

360

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

October 31, 2018

Conditions

Curable Hepatitis B Virus-Related Hepatocellular Carcinoma

Interventions

PROCEDURE

curative resection

DRUG

thymalfasin

1.6mg twice a week, 12 months

DRUG

nucleoside analog (suggest to use entecavir)

Trial Locations (1)

Zhongshan Hospital, Shanghai